5/30/14 7:21 AM ET (Benzinga)
Pre-open moversUS stock futures traded slightly lower in early pre-market trade. Data on consumer spending for April will be released at 8:30 a.m. ET, while the Chicago PMI for May will be released at 9:45 a.m. ET. The Reuter's/University of Michigan's consumer sentiment index for May will be released at 9:55 a.m. ET. Futures for the Dow Jones Industrial Average dropped 7 points to 16,674.00, while the Standard & Poor's 500 index futures fell 1.70 points to 1,916.20. Futures for the Nasdaq 100 index declined 1.25 points to 3,734.25.
A Peek Into Global Markets
European markets were mostly lower today, with the Spanish Ibex Index gaining 0.32%, STOXX Europe 600 Index dropping 0.10%. German DAX 30 index fell 0.05%, French CAC 40 Index slipped 0.60% and London's FTSE 100 Index dropped 0.20%. Spanish consumer price index increased 0.2% in May, while German retail sales dropped 0.9% in April.
In Asian markets, Japan's Nikkei Stock Average dropped 0.34%, Hong Kong's Hang Seng Index rose 0.31%, China's Shanghai Composite Index declined 0.07% and India's BSE Sensex tumbled 0.07%. Japan's consumer price index climbed 3.2% in April.
Broker Recommendation
Analysts at Deutsche Bank downgraded Infoblox (NYSE: BLOX) from buy to hold. The target price for Infoblox has been lowered from $30 to $18.
Infoblox's shares tumbled 32.94% to $13.76 in pre-market trading.
Breaking news
- Exponent (NASDAQ: EXPO) today announced that its Board of Directors has authorized an additional stock repurchase plan. To read the full news, click here.
- ReachLocal (NASDAQ: RLOC) today announced the launch of ReachEdge to help SMEs get more customers from their marketing spend. To read the full news, click here.
- QIAGEN (NASDAQ: QGEN) today announced a collaboration with Eli Lilly and Company (NYSE: LLY) to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. To read the full news, click here.
- Myriad Genetics (NASDAQ: MYGN) announced the presentation of new data at the American Society of Clinical Oncology (ASCO) meeting this week that supports the clinical efficacy of its BRAC Analysis CD and HRD tests in predicting platinum based therapy response for breast cancer patients. To read the full news, click here.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
No comments:
Post a Comment